Overview
Gene editing firm's Q4 net loss beat analyst estimates
Collaboration and R&D revenue decreased due to prior milestone revenue recognition
Company maintains strong cash position with runway into Q3 2027
Outlook
Editas plans IND/CTA submission for EDIT-401 by mid-2026
Result Drivers
LOWER R&D EXPENSE: Research and development expenses decreased by $21.2 million to $27.4 million for the three months ended December 31, 2025, compared to $48.6 million for the same period in 2024.
Company press release: ID:nGNX8VPqVz
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Collaboration and other research and development revenue | $24.70 mln | ||
Q4 EPS | -$0.06 | ||
Q4 Net Income | Beat | -$5.62 mln | -$24.29 mln (9 Analysts) |
Q4 Basic EPS | -$0.06 | ||
Q4 Operating Expenses | $32.50 mln | ||
Q4 Operating Income | -$7.76 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Editas Medicine Inc is $4.00, about 100% above its March 6 closing price of $2.00
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)